Roivant Sciences Ltd.

US$38.88As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ROIVHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR 25.75%
Div yield —
ROE (8.52%)
Biotechnology
Beta (5Y) 1.20
PE TTM —
TSR TTM 94.50%
Mkt cap US$28.08B
ROIC (117.33%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$46
18.81%
(56.79%)
Hold 7|10|2|10|2
3Q26
4Q26
1Q27
2Q27
Earnings per share$
0.53
0.56
0.61
0.61
(1.25%)
6.00%
19.98%
22.92%
Revenue$B
3.419
3.484
3.504
3.422
(0.74%)
0.13%
(2.18%)
(2.81%)
Peers (US$28.08B)
Cap (US$)
PE
2.709B
—
2.071B
5.627x
Capital
TTM
5Y
10Y
Leveragex
1.310
0.450
0.419
EBIT/Intx
1.290
0.337
0.301
Own earn%
(632.30)
45.82
38.39
Sh yield%
32.75
16.24
25.97
Owners
Insiders/Inst%
13.86
32.27
Short interest%
1.85
SBC / revenue%
4.16
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
25
Op margin range%
15–18
$1 testx
−0.2
Incr. ROIC%
9